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Prior surveillance has shown that higher rates of morbidity and
mortality related to asthma occur among African-Americans
compared to other ethnic groups. OBJECTIVE: to assess uti-
lization and costs for medical services and prescription medica-
tions among African-American patients with asthma whom does
Medicaid cover. METHODS: Medical services claims with a
primary diagnosis code for asthma (ICD-9 CM 493) during cal-
endar year 2002 for recipients of African-American ethnicity
were extracted from a state Medicaid claims database. Asthma-
related prescription claims were extracted using unique and
anonymous recipient codes obtained from the medical claims.
Claims for recipients aged 65 years and older were excluded.
Cost data were from the perspective of Medicaid. RESULTS:
There were 654 African-American recipients identiﬁed with
asthma. Among these, the highest rates for asthma occurred
among males under 21 years (43 per 1000) and females over 20
years (38 per 1000). Medicaid paid over $570,000 for asthma-
related health care services for African-American recipients.
Mean costs per visit were $3409 for hospitalizations, $159 for
emergency department (ED) visits, and $102 for outpatient
visits. Compared to females, males had a higher rate of inpatient
admissions (32 per 10,000), ED visits (170 per 10,000), and out-
patient visits (68 per 1000) for asthma. Compared to children,
adults over 20 years had a higher rate of inpatient admissions
(30 per 10,000), ED visits (150 per 10,000), and outpatient visits
(68 per 1000) for asthma. The total cost for prescription med-
ications equaled approximately $256,000, at an average cost of
$49 per prescription. Of the prescription claims for asthma-
related medications, about 60% were for quick-relief medica-
tions and 40% were for maintenance drugs. Among claims for
maintenance drugs, most were for leukotriene inhibitors. CON-
CLUSIONS: Males utilized medical services more frequently
than females, as did adults compared to children. Quick-relief
medications accounted for most of the prescription claims.
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BUDGET IMPACT ANALYSIS: COMBINATION FLUTICASONE
AND SALMETEROL FOR ASTHMA
Mauskopf JA1, Shih T2, Baker T3, Borker R4, Stanford RH4, Jhingran P4
1RTI Health Solutions, Research Triangle Park, NC, USA; 2The
University of Texas M.D. Anderson Cancer Center, Houston,TX, USA;
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OBJECTIVES: The objective of this study was to estimate the
budget and health impact of increasing use of combination 
ﬂuticasone propionate and salmeterol (FS) in a managed care for-
mulary by adults with mild to moderate persistent asthma.
METHODS: An EXCEL-based model was developed to estimate
the impact of increasing use of FS in the mix of treatments used
for persistent asthma including ﬂuticasone proprionate (FP), sal-
meterol (SAL), other inhaled corticosteroids (ICS), leukotriene
modiﬁers (LTM), other combination therapies, and short-acting
beta-agonists (SABA). The analysis was conducted from a health
plan’s perspective. Efﬁcacy, adverse events, epidemiology, com-
pliance, and cost data were obtained from published estimates
including randomized controlled trials. The health plan was
assumed to have 1,000,000 members. Treatment mix for asthma
was based on market research data. An exponential relationship
between compliance and efﬁcacy was assumed for compliance
rates above thirty percent. RESULTS: A total of 29,050 persons
were estimated to seek treatment for persistent asthma in the
health plan. Model results comparing an FS market share of 25%
to one of 30% in the health plan show total asthma treatment
cost increases of $0.03/per member (all enrollees) per month
(PMPM) and $0.96/per asthmatic patient per month. The budget
impacts were accompanied by an annual increase of 56,555
rescue-free days and reduction of 155 exacerbations. Results are
sensitive to changes in drug costs, drugs used before FS, com-
pliance with asthma drugs, and the relationship between com-
pliance and efﬁcacy with PMPM changes ranging from a saving
of $0.01/PMPM to an increase of $0.06/PMPM for feasible alter-
native scenarios. CONCLUSION: An increase in market share
of FS will have a small impact on the overall budget of a health
plan in our base case and feasible alternative scenarios. This
budget increase will be accompanied by reductions in exacerba-
tions and other disease symptoms.
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EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE
MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO
MEDICAID POPULATION
Heaton PC, Guo JJ, Jang R, Cluxton RJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: To determine the impact of leukotriene modiﬁers
on subsequent emergency room visits, hospitalizations and
steroid bursts; and to estimate whether leukotriene modiﬁer use
is cost-beneﬁcial. METHODS: A retrospective, longitudinal
study of 5541 adult asthmatic patients in the Ohio Medicaid
program used rate of adverse outcomes and logistic regression
to determine the impact of leukotriene modiﬁer use on three
outcome measures: emergency room visits, hospitalizations, or
steroid bursts. Propensity scores were used to control selection
bias inherent in drug treatment selection in natural databases. A
cost-beneﬁt analysis was also calculated. The cost-beneﬁt ratio
was deﬁned as the difference in asthma drug costs between the
leukotriene users and nonusers divided by the difference in
outcome costs between the users and nonusers. RESULTS:
Leukotriene modiﬁer users had 13.9 events per one hundred
patients versus the nonusers who had 11.1 events per one
hundred patients. In logistic regression models, the use of
leukotriene modiﬁers did not signiﬁcantly impact the odds of any
outcome measures: Emergency Room Visits OR 1.163, 95% CI
0.913–1.483; Hospitalizations OR 1.061, 95% CI 0.685–1.643;
Steroid Bursts OR 1.362, 95% CI 0.933–1.988. The mean cost
of all asthma drugs received by leukotriene modiﬁer users was
$327.19 and for nonusers was $186.70. The mean cost of all
outcome measures was $104.80 for leukotriene modiﬁer users
and $99.89 for nonusers. This resulted in a cost beneﬁt ratio
equal to 28.6. CONCLUSIONS: Logistic regression models
suggest that the use of leukotriene modiﬁers did not have a 
positive or negative signiﬁcant effect on any of the outcome vari-
ables. Leukotriene modiﬁer users did have higher rates of adverse
outcomes. The cost beneﬁt analysis shows that there was a total
net loss to Ohio Medicaid. The results suggest that leukotriene
modiﬁer users do not have improved outcomes or improved 
cost-beneﬁt when compared to nonusers.
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RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN
COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE
NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND
ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY
USING MULTIVARIATE LOGISTIC REGRESSION
Mehta R, Cady P
Idaho State University, Salt Lake City, UT, USA
OBJECTIVE: To evaluate the resource utilization after intro-
duction of new treatment guidelines in Asthma (1997).
METHODS: Paid claims for pharmacy services during the period
1994 through 2000 were collected. Chronic users (CUs): using
more than 10 canisters of beta-inhaler/year. Patients were further
categorized: CHBYAi (CUs, using some anti-inﬂammatory 
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medication; “appropriate therapy”) and CHBNAi (CUs not
using any anti-inﬂammatory medication). Univariate analyses for
continuous variables was performed using Mann-Whitney U test;
and multivariate logistic regression was performed to predict the
probability of being on appropriate therapy. RESULTS: A total
of 1127 chronic users were identiﬁed (474 before and 653 after
the introduction of the guidelines). A higher proportion of
CHBYAi patients were found after the introduction of the guide-
lines (7%, Chi-square test, p-value = 0.041). However, both
before and after the introduction of the guidelines the CHBNAi
had signiﬁcantly fewer asthma-related total (physician, ER and
hospital) visits and costs (all p-value = 0.000). Multivariate logis-
tic regression results indicated that total asthma-related visits
was signiﬁcantly associated with the odds of being on appropri-
ate therapy. Before the guidelines, for every asthma related visit
the odds of being on appropriate guidelines was found to be
1.544 (95% CI: 1.327–1.797); for every asthma related visit the
odds of being on appropriate therapy was found to be 1.937
(95%CI: 1.624–2.309). CONCLUSION: We would have
expected a higher health care utilization (visits & cost) for the
CHBNAi group but we could not conclude this.
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COSTS FOR ASTHMA-RELATED MEDICAL SERVICES 
AND PRESCRIPTION MEDICATIONS IN A STATE 
MEDICAID PROGRAM
D’Souza A, Smith MJ
West Virginia University, Morgantown, WV, USA
Previous studies have shown that costs for asthma care tend to
be higher among recipients of Medicaid compared to patients
covered by private insurance. OBJECTIVE: Report the costs for
asthma-related health care in a state Medicaid Program.
METHODS: Medicaid medical services claims with a primary
ICD-9 diagnosis code for asthma dated 2002 were extracted.
Matching claims for asthma-related prescription medications
also were collected. Costs for outpatient visits, emergency
department (ED) visits, and prescriptions were based on dollars
reimbursed by Medicaid. Costs for hospitalizations were esti-
mated based on average DRG reimbursements. RESULTS: There
were 16,573 recipients with claims for asthma. Among demo-
graphic groups, a majority of recipients were younger than 15
years (44%), female (58%), and white (93%). Medicaid paid
roughly $12.9 million for asthma-related medical services and
prescriptions, or an average of $779 per recipient with asthma.
A majority of the dollars were paid for services and prescriptions
utilized by adults between 21 and 64 years of age (49%), females
(61%), and caucasians (93%). Hospitalization costs amounted
to $3.5 million (27% of the total) at an average cost of nearly
$4000 per admission. ED costs equaled over $619,000 (5% of
the total) at an average cost of $169 per visit. Outpatient costs
were nearly $2.4 million (19% of the total) at an average cost
of $83 per visit. Prescription costs totaled $6.2 million (48% of
the total) for an average cost of $51 per prescription. A major-
ity of the dollars paid for prescriptions were for leukotriene mod-
iﬁers (33%), short-acting beta-agonists (23%), and inhaled
corticosteroids (21%). CONCLUSIONS: Asthma is responsible
for a substantial consumption of economic resources of the Med-
icaid Program. Roughly half of the dollars Medicaid spends for
asthma care is for medical services and half for prescription
drugs. Hospitalizations account for a majority of medical ser-
vices costs.
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THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-
SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING
FOLLOWING OVER-THE-COUNTER AVAILABILITY 
OF LORATADINE
Hansen RA,Trygstad TK
University of North Carolina—Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: This study evaluates the effect of over-the-
counter (OTC) availability of loratadine on utilization and
spending in a state Medicaid population without OTC coverage.
Using a subset of nearly 100,000 enrollees before and after
loratadine OTC availability, the speciﬁc objectives of this study
were to: 1) evaluate product switching behavior; 2) describe non-
sedating antihistamine utilization patterns; and 3) describe non-
sedating antihistamine expenditures and their response to OTC
availability. METHODS: The study was conducted retrospec-
tively using paid pharmacy claims for a subset of Medicaid 
beneﬁciaries. Non-sedating antihistamine use was evaluated for
two 12 month intervals encompassing July 1, 2001 through June
30, 2003. Within each interval, the rate of product switching
between the ﬁrst 5 months and last 5 months was evaluated.
Trends in utilization and spending were tracked for the entire
24-month period. RESULTS: Beneﬁciaries using loratadine in the
OTC availability interval were 2.4 (95% CI; 2.08–2.41) times
more likely to switch to a different non-sedating antihistamine
and 1.09 (95% CI: 1.08–1.12) times more likely to not have a
non-sedating antihistamine claim than beneﬁciaries in the non-
OTC availability interval. The largest gain in market share was
observed for cetirizine, although desloratadine accounted for the
largest switch rate from loratadine. During the ﬁrst 12 months
of the study, non-sedating antihistamine expenditures increased
by nearly $28,000 per month. Despite availability of a less costly
alternative, expenditures increased by $13,000 per month during
the last 12 months. CONCLUSIONS: Although utilization and
spending tapered slightly after the introduction of loratadine
OTC, the majority of beneﬁciaries using loratadine switched to
a covered alternative once the OTC product was on the market.
Given the potential cost-savings associated with OTC loratadine
(compared to the prescription only competitors) and the high
likelihood of switching, it appears that state Medicaid programs
should consider coverage of both prescription and OTC 
products.
ASTHMA/ALLERGY (including ARDS)
ASTHMA/ALLERGY (including ARDS)—Quality Of
Life/Adherence/Patient Preferences
PAA15
INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN
ASTHMA USING Q METHODOLOGY
Butler MG1, Schumock GT2,Wilken L2, Jaffe HA2, Mrtek R2
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OBJECTIVE: To identify patient behaviors that affect adherence
regarding asthma and its management using Q-methodology.
New insight into patient attitudes may facilitate further devel-
opment of interventions, which remove barriers affecting adher-
ence in asthma. While many theoretical frames have been
proposed, this is the ﬁrst application of Q-methodology to this
problem. METHODS: A literature search, and interviews with
clinicians and patients were used to create a concourse of reasons
for non-adherence in asthma. The raw set of ideas in the con-
course were deﬁned, clariﬁed and combined into more mean-
